Radium/Xofigo Medication Does

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 16, specifically the Michael E. DeBakey VA Medical Center in Houston, Texas, is procuring Xofigo (Radium Ra-223) medication for treating veterans with castration-resistant prostate cancer symptomatic bone metastases. The solicitation requires contractors to provide 30 single unit doses of this radioactive medication annually for use in the Nuclear Medicine Department. Offerors must be active in the System for Award Management (SAM) and demonstrate two years of past performance in similar services. The contract evaluation will be based on three factors: Technical capability, Price, and Past Performance, with contractors required to complete a comprehensive past performance questionnaire. The solicitation was posted on August 25, 2025, with proposals due by September 12, 2025, and past performance references must be submitted by September 3, 2025.

This unrestricted procurement does not utilize any set-aside designations and falls under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) with a size standard of 1,300 employees. The contract structure includes a base year from October 1, 2025 to September 30, 2026, with four optional one-year periods extending through September 30, 2030, potentially creating a five-year contract duration. Contractors must provide specialized courier services licensed to transport radioactive material and calibrate doses within +/- 20 percent of specified requirements. Delivery must occur Monday through Friday between 8:00 AM and 4:30 PM CST, excluding federal holidays, directly to the Nuclear Medicine Department at the Michael E. DeBakey VA Medical Center in Houston, Texas. Orders will be placed by Staff Nuclear Medicine Technologists, and the contractor must maintain precise handling protocols for this highly regulated radioactive pharmaceutical product.